Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

MJ-355: a new K(ATP) channel opener with antihypertensive and cardioprotective effects

Dec. 22, 1999

Pretreatment with complement inhibitor significantly reduces cardiac, brain damage following CPB

Dec. 22, 1999

Bristol-Myers Squibb seeks regulatory approvals worldwide for Vanlev

Dec. 21, 1999

New cardiovascular agents from Yamanouchi

Dec. 21, 1999

German launch and local distributor announced for Tanabe's ACE inhibitor

Dec. 21, 1999

CV Therapeutics receives SBIR grant to study effects of adenosine in angiogenesis

Dec. 21, 1999

AVI BioPharma's restenosis antisense compound enters phase I trials

Dec. 17, 1999

Novel inotropic agent EGIS-9377: potential advantages in the treatment of CHF

Dec. 16, 1999

Indian scientists explore mechanism of cardioprotective effect of PAF antagonist

Dec. 15, 1999

Concor COR cleared for marketing in Germany as heart failure treatment

Dec. 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...